|
1
|
Zur Hausen H: Papillomaviruses in human
cancer. Cancer. 15:1692–1996. 1987.
|
|
2
|
Kumvongpin R, Jearanaikool P, Wilailuckana
C, Sae-Ung N, Prasongdee P, Daduang S, Wongsena M, Boonsiri P,
Kiatpathomchai W, Swangvaree SS, et al: High sensitivity,
loop-mediated isothermal amplification combined with colorimetric
gold-nanoparticle probes for visual detection of high risk human
papillomavirus genotypes 16 and 18. J Virol Methods. 234:90–95.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shin TH, Pankhong P, Yan J, Sardesai NY
and Weiner DB: Induction of robust cellular immunity against HPV6
and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen. Hum
Vaccin Immunother. 8:470–478. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
DasGupta T, Nweze EI, Yue H, Wang L, Jin
J, Ghosh SK, Kawsar HI, Zender C, Androphy EJ, Weinberg A, et al:
Human papillomavirus oncogenic E6 protein regulates human
β-defensin 3 (hBD3) expression via the tumor suppressor protein
p53. Oncotarget. 7:27430–27444. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun L, Zhang G, Lei T, Huang C, Song T and
Si L: Two different HPV-11E6 fusion proteins trap p53 in the
cytoplasm and induce apoptosis. Cancer Biol Ther. 7:1909–1915.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Y, Chiriva-Internati M, Grizzi F,
Salati E, Roman JJ, Lim S and Hermonat PL: Rapid induction of
cytotoxic T-cell response against cervical cancer cells by human
papillomavirus type 16 E6 antigen gene delivery into human
dendritic cells by an adeno-associated virus vector. Cancer Gene
Ther. 8:948–957. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Filippova M, Evans W, Aragon R, Filippov
V, Williams VM, Hong L, Reeves ME and Duerksen-Hughes P: The small
splice variant of HPV16 E6, E6, reduces tumor formation in cervical
carcinoma xenografts. Virology 450–451. 1–164. 2014.
|
|
8
|
Shi GN, Zhang CN, Xu R, Niu JF, Song HJ,
Zhang XY, Wang WW, Wang YM, Li C, Wei XQ and Kong DL: Enhanced
antitumor immunity by targeting dendritic cells with tumor cell
lysate-loaded chitosan nanoparticles vaccine. Biomaterials.
113:191–202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baert T, Garg AD, Vindevogel E, VAN
Hoylandt A, Verbist G, Agostinis P, Vergote I and Coosemans AN: In
vitro generation of murine dendritic cells for cancer
immunotherapy: An optimized protocol. Anticancer Res. 36:5793–5801.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hiraiwa A, Kiyono T, Segwa K, Utsumi KR,
Ohashi M and Ishibashi M: Comparative study on E6 and E7 genes of
some cutaneous and genital papillomaviruses of human origin for
their ability to transform 3Y1 cells. Virology. 192:102–111. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tao M, Kruhlak M, Xia S, Androphy E and
Zheng ZM: Signals that dictate nuclear localization of human
papillomavirus type 16 oncoprotein E6 in living cells. J Virol.
77:13232–13247. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liang XH, Volkmann M, Klein R, Herman B
and Lockett SJ: Co-localization of the tumor-suppressor protein p53
and human papillomavirus E6 protein in human cervical carcinoma
cell lines. Oncogene. 8:2645–2652. 1993.PubMed/NCBI
|
|
13
|
Kubicka-Sierszen A and Grzegorczyk JŁ: The
influence of infectious factors on dendritic cell apoptosis. Arch
Med Sci. 11:1044–1051. 2015.PubMed/NCBI
|
|
14
|
Wang JJ, Li YF, Jin YY, Wang X and Chen
TX: Effects of Epstein-Barr virus on the development of dendritic
cells derived from cord blood monocytes: An essential role for
apoptosis. Braz J Infect Dis. 16:19–26. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kehmeier E, Rühl H, Voland B, Stöppler MC,
Androphy E and Stöppler H: Cellular steady-state levels of ‘high
risk’ but not ‘low risk’ human papillomavirus (HPV) E6 proteins are
increased by inhibition of proteasome-dependent degradation
independent of their p53 and E6AP binding capabilities. Virology.
299:72–87. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li X and Coffino P: High-risk human
papillomavirus E6 protein has two distinct binding sites within
p53, of which only one determines degradation. J Virol.
70:4509–4516. 1996.PubMed/NCBI
|
|
17
|
Martinez-Zapien D, Ruiz FX, Poirson J,
Mitschler A, Ramirez J, Forster A, Cousido-Siah A, Masson M, Vande
Pol S, Podjarny A, et al: Structure of the E6/E6AP/p53 complex
required for HPV-mediated degradation of p53. Nature. 28:541–545.
2016. View Article : Google Scholar
|
|
18
|
Huibregtse JM, Scheffner M and Howley PM:
Cloning and expression of the cDNA for E6-AP, a protein that
mediates the interaction of the human papillomavirus E6 oncoprotein
with p53. Mol Cell Biol. 13:775–784. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Manjarrez ME, Ocadiz R, Valle L, Pacheco
C, Marroquin A, De la Torre C, Selman M and Gariglio P: Detection
of human papillomavirus and relevant tumor suppressors and
oncoproteins in laryngeal tumors. Clin Cancer Res. 12:6946–6951.
2006. View Article : Google Scholar : PubMed/NCBI
|
